These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33238517)

  • 1. A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery.
    Chen YJ; You GR; Lai MY; Lu LS; Chen CY; Ting LL; Lee HL; Kanno Y; Chiou JF; Cheng AJ
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
    You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
    BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer.
    You GR; Chang JT; Li YL; Chen YJ; Huang YC; Fan KH; Chen YC; Kang CJ; Cheng AJ
    Front Oncol; 2021; 11():681717. PubMed ID: 34307149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
    Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
    Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer.
    Cui F; Hu J; Fan Y; Tan J; Tang H
    Oncol Lett; 2018 Apr; 15(4):5712-5720. PubMed ID: 29552205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.
    Chen CH; Chang AY; Li SH; Tsai HT; Shiu LY; Su LJ; Wang WL; Chiu TJ; Luo SD; Huang TL; Chien CY
    Mol Cancer; 2015 Apr; 14():83. PubMed ID: 25889801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5.
    Qin X; Guo H; Wang X; Zhu X; Yan M; Wang X; Xu Q; Shi J; Lu E; Chen W; Zhang J
    Genome Biol; 2019 Jan; 20(1):12. PubMed ID: 30642385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of hub genes involved in cisplatin resistance in head and neck cancer.
    Chaudhary RK; Khanal P; Mateti UV; Shastry CS; Shetty J
    J Genet Eng Biotechnol; 2023 Jan; 21(1):9. PubMed ID: 36715825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.
    Chen J; Chen H; Yang H; Dai H
    Biomed Pharmacother; 2018 Apr; 100():233-239. PubMed ID: 29432994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype.
    Chiu CC; Lee LY; Li YC; Chen YJ; Lu YC; Li YL; Wang HM; Chang JT; Cheng AJ
    Cancer Gene Ther; 2013 Nov; 20(11):606-15. PubMed ID: 24201869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
    Roh JL; Kim EH; Park JY; Kim JW
    Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spindle pole body component 25 regulates stemness of prostate cancer cells.
    Cui F; Tang H; Tan J; Hu J
    Aging (Albany NY); 2018 Nov; 10(11):3273-3282. PubMed ID: 30408771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer.
    Wang PW; Abedini MR; Yang LX; Ding AA; Figeys D; Chang JY; Tsang BK; Shieh DB
    Int J Cancer; 2014 Dec; 135(12):2760-9. PubMed ID: 24771612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.